Amiodarone has multiple pharmacological effects in heart. Electrophysiological data suggest that among its other effects, amiodarone is a sodium channel blocker. Using a radioligand assay, we determined whether amiodarone interacted with a previously described receptor for type I agents associated with the cardiac sodium channel. Received January 12, 1988; accepted February 7, 1989. that amiodarone reduced the maximum rate of rise of the action potential upstroke (VJ in guinea pig papillary muscle during voltage-clamp experiments. Yabek et al 5 obtained similar results with canine Purkinje fibers and ventricular muscle. The latter three studies showed that amiodarone exhibited both frequency-dependent and voltage-dependent block and suggested that amiodarone, like class I agents, blocks inactivated sodium channels.
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We have recently developed a radioligand assay for a receptor for the class I agents that is associated with the cardiac sodium channel. 6 - 8 Binding of class I agents to this receptor is saturable, reversible, stereospecific, and occurs at pharmacologically relevant concentrations with a similar rank order of potency in vitro and in vivo. We hypothesized that amiodarone, because of its class I-like effect on conduction time and V^, would also bind to the class I drug receptor at pharmacologically relevant concentrations. Other class III agents have little effect as sodium channel blockers except at suprapharmacological levels. 9 - 10 These data suggested that they should have little affinity for the class I receptor. Therefore, we compared the abil-ities of amiodarone and other class III agents to bind to the class I receptor associated with the cardiac sodium channel.
Materials and Methods

Myocyte Preparation
Cardiac myocytes were isolated from adult male Sprague-Dawley rats (200-250 g) by the method of Kryski et al. 11 Rats were killed by cervical dislocation, and the heart was rapidly removed. The aorta was cannulated, and the heart was perfused in a retrograde fashion in a Langendorff perfusion apparatus. The heart was perfused and later incubated with a series of solutions that were equilibrated with 95% O 2 -5% CO 2 at 37° C. The solutions were based on Joklik's Minimal Essential Medium (MEM) supplemented with 1.2 mM MgSO 4 and 1 mM DLcarnitinine (MEM). They included a rinse solution (MEM), a digestion solution (MEM with 0.1% wt/ vol fatty acid-free bovine serum albumin [BSA] and 0.1% collagenase), a calcium solution (MEM with 1 mM CaCl 2 and 1% fatty acid-free albumin), and an incubation solution (MEM with 50 pM CaCl 2 and 1% diatyzed BSA). The heart was perfused at 20° C for 5 minutes with rinse solution and then perfused at 37° C for 20 minutes with digestion solution. The ventricles were then removed, minced with scissors, and rinsed at 37° C for 15 minutes with calcium solution. Calcium solution was then removed by aspiration, and the tissue pieces were incubated at 37^ C for 15 minutes with digestion solution in a shaking water bath. Dispersed cells were decanted into a plastic centrifuge tube, and the residual tissue was shaken again with digestion solution. This procedure resulted in almost total dispersion of the heart. The pooled myocytes were then filtered through a 185-fim silkscreen mesh, collected by gentle centrifugation, and rinsed with incubation solution. The cells were again collected by gentle centrifugation and resuspended in incubation solution. This method routinely yielded about 100 mg (dry wt) of myocytes, which corresponds to 2xlO 7 cells.
11 - 12 The cells were 82-92% viable rod-shaped cells that excluded trypan blue. The cells maintained a resting membrane potential of -75 mV to -80 mV and have been metabolically characterized by Kryski et al. 11 
Radioligand Binding
Myocytes (6xlO 5 per assay) in 50 /A incubation buffer were incubated with 1.3 piM sea anemone toxin II (ATX), 13 nM pHJbatrachotoxinin A 20a-benzoate (BTXB) (50 Ci/mM), and 0.13 mM tetrodotoxin for 45-60 minutes at 37° C. Tetrodotoxin was added to prevent depolarization induced by sodium influx. Various concentrations of drugs and toxins were included in the incubations. Assays were done in parallel with tubes containing 0.4 mM aconitine to define nonspecific binding. Reactions were terminated by adding 10 ml Krebs-Henseleit-BSA buffer, which consisted of (mM) NaCl 127, KC1 2.33, KH 2 The rationale for the incubation and filtration conditions was described by Sheldon et al. 6 The conditions provide a maximal reduction in background and scatter with a minimal reduction in specific binding. The total wash time is 45 seconds. Initial control experiments showed that under these conditions, less than 10% of the specifically bound [ 3 H]BTXB dissociated from the complex. Under these reaction conditions (13 nM pHJBTXB, 1.3 fiM ATX), about 60-75% of the total radioactivity retained on the filters was bound specifically to the receptor.
Amiodarone Preparation
Amiodarone was prepared daily as a 25 mM stock solution in warm 100% ethanol and then diluted with incubation solution. The amiodarone did not form visible precipitates at final concentrations less than 1 mM. Control experiments showed that ethanol up to 2% did not inhibit [ 
Aqueous Concentrations of Amiodarone
Amiodarone concentrations were measured by high-performance liquid chromatography, 13 which has a coefficient of variation of less than 7%. The high-performance liquid chromotography system consisted of a Waters 510 pump (Waters Associates, Milford, Massachusetts), WISP sample injector (Waters), reverse-phase Brownlee RP18 (10 fim) column (220 mmx4.6 mm i.d.) (Brownlee Lales, Santa Clara, Calfornia), Shimadzu ultraviolet detector operated at 254 nm Shimadzu Corporation, Kyoto, Japan), and a Hewlett-Packard 3390A integrator (Hewlett-Packard, Mississauga, Ontario, Canada) with a chart speed of 0.5 cm/min. The mobile phase was methanol-water-ammonium hydroxide (89.7:10:0.3 vol/vol) with a flow rate of 3 ml/min.
To determine the fraction of amiodarone in the free aqueous phase, a known amount of amiodarone was added to incubation mixtures. The tubes were then centrifuged in an HS-N centrifuge at 2,500 rpm for 30 seconds, and the amount of amiodarone was determined in the supernatant fluid and cell pellet. The results showed that 13 ±3% of the amiodarone remained in the cell-free supernatant fluid. We also showed that this partitioning is very rapid; there was no significant time dependence in partitioning from 0.5 to 45 minutes after addition of amiodarone. The same fraction remained in the supernatant fluid 10 100 1000 10000 Figure 1 . The inhibition by the drugs is dose-dependent and follows a sigmoid curve characteristic of ligand binding to a single class of saturable sites. In this experiment, the estimated IQo of amiodarone is 3.6 fiM and that of iV-acetylprocainamide is 2,100 /AM. These are illustrative results of single experiments representative of those reported in Table 1 .
The mean IQo values for inhibition of [ Table 1 . The mean IQo values for amiodarone and desethylamiodarone are 3.6 fiM and 3.1 fiM, respectively, whereas those for sotalol, bretylium, W-acetylprocainamide, and bethanidine are about 1,000-3,000 FU,M. Table 1 also contains the clinically effective serum concentrations and estimates of the concentrations at which these drugs block the sodium channel. The latter two sets of data are taken from the previously published works of others, which are listed in the table legend. In Figure 2 , we have compared the IQo values from radioligand experiments with the clinically effective serum concentrations of the drugs. The values for type III drugs are represented in Figure 2 as open symbols in a plot of log (IQo) versus log (serum concentration). For comparison, we have included similar data for eight type I antiarrhythmic drugs, which are thought to be effective clinically by causing sodium channel blockade. These are plotted as closed symbols. In contrast to the class I drugs, which have the same rank order of potency in vivo and in vitro and have IQo values at pharmacologically relevant concentrations, the type III drugs have neither the same rank order of potency nor are their IQo values at pharmacologically relevant concentrations. The relations between IQo, serum concentration, and sodium channel blocking ability will be discussed below. 7 Amiodarone markedly reduced the B,ĉ apacity for pHJBTXB (Figure 3 ).
Discussion.
Amiodarone is an efficacious antiarrhythmic drug whose mode of action is unclear. 1 Although it has been categorized as a class III agent on the basis of its effect on action-potential duration, there is electrophysiological evidence that it has properties of a sodium channel blocker. 2 -5 This study assessed the ability of amiodarone to bind to a receptor for the class I antiarrhythmic agents associated with the cardiac sodium channel. 6 The marked lipophilicity of amiodarone raises several issues regarding the distribution of amiodarone and its mode of access to the receptor associated with the sodium channel. Chatelain and Laruel 22 have shown that the distribution coefficient of amiodarone at pH 7.4 between red blood cell membranes and an aqueous phase is about 15,000. The partition coefficient of neutral amiodarone was much higher (approximately 10 6 ). Our finding that 13±3% of amiodarone remained in the aqueous cell-free phase is not corrected for the relative volumes of the aqueous phase and the cell membranes, which occupy only a small fraction of total cell volume. Thus, although the fraction of amiodarone in the supernatant aqueous phase seems high, it probably reflects the large difference in the volumes of the two phases.
The distribution of a high proportion of amiodarone into the lipid cell membrane may be important in the pathway by which amiodarone (and indeed other antiarrhythmic drugs 23 ) reach the receptor. The present study does not address this point. However, it should be stressed that IQo values for the interaction of ligands with their receptors are conventionally expressed in terms of their aqueous concentrations. We have adopted this convention here although it remains possible that amiodarone does reach the sodium channel receptor via the membrane lipid pool.
One possible mechanism of action of amiodarone on [ membrane. However, the sigmoidal concentrationresponse curve of amiodarone (Hill number l.l±0.1) speaks to a single class of saturable sites.
Finally, the physiochemical properties of amiodarone dictate its distribution between the aqueous phase and the lipid membrane. Therefore, the possibility that amiodarone partitions differently for live and dead cells, which both have lipid membranes, is unlikely. This is noteworthy because had amiodarone partitioned preferentially to dead cells, then the variable portion (8-18%) of dead cells might have spuriously influenced the apparent ICJO of amiodarone.
The mean estimated IQo for amiodarone in this assay was 3.6 fiM. In patients being treated with amiodarone for ventricular tachyarrhythmias, the serum concentration is similar, about 2.5 ^.M. 7 This estimate is strikingly similar to the IQo of amiodarone for the receptor in our assay and suggests that one of the clinical effects of amiodarone is sodium channel blockade.
This work also sheds some insight into the nature of the interaction of amiodarone with the sodium channel. Previous work by Mason et al 3 -4 suggested that amiodarone binds preferentially to inactivated channels with a K d of about 20 NM. The estimated affinities for the rested and activated states were much weaker. Given the extreme lipophilicity of amiodarone, it is likely that the estimate of 20 /iM is misleadingly high and should be viewed as an upper limit, but the conclusion that the drug binds to inactivated channels remains valid. Similarly, Follmer et al 24 concluded from single cell voltageclamp experiments that amiodarone bound with high affinity to both rested (estimated K^ 3 jtM) and inactivated channels (estimated AT d 0.1 ^M) but not to activated channels although their estimates are based on assumed rather than measured concentrations of amiodarone. The results in Figure 3 6 (also, Hill, Duff, and Sheldon, unpublished results). In equilibrium competition experiments, the toxins and drugs are in a complex and dynamic interaction with sodium channels in various states. To account for the inhibition of pHJBTXB binding by amiodarone, it is not necessary to invoke amiodarone interaction with toxin-activated channels; in fact, amiodarone may be effective by stabilizing channels to which toxins are not bound. Thus, both electrophysiological and biochemical data support the idea that amiodarone binds with high affinity to a site associated with either inactivated sodium channels or channels not activated by toxins. It is clear that amiodarone has properties of both class I and class III agents. It should be noted that the data in this report do not rule out an alternative but less likely explanation of the Scatchard data (that amiodarone irreversibly inhibits [3H]BTXB binding).
We found that bretylium, sotalol, bethanidine, and JV-acetylprocainamide, in contrast to amiodarone, had much less affinity for the class I receptor and only inhibited [ Table 1 and Figure 2 . The electrophysiological data are derived from several techniques. These electrophysiological data are only estimates because concentrations producing maximum effects were not assessed. However, it has been shown ( Table 1) that bretylium, sotalol, bethanidine, and Nacetylprocainamide function as very weak sodium channel blockers when studied with electrophysiological methods. The clinically effective concentrations for these drugs are also listed in Table 1 . Bretylium, sotalol, and Af-acetylprocainamide are clinically effective at much lower concentrations than the concentrations at which they block [ 3 H]BTXB binding. Thus, their antiarrhythmic effect is unlikely to be due to interaction with the class I receptor associated with cardiac sodium channels.
In conclusion, amiodarone binds to a receptor for class I antiarrhythmic agents associated with the cardiac sodium channel at a concentration similar to its myocardial concentration. Other class III agents also bind to this site but do so at concentrations far higher than occur clinically.
